Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Autophagy role(s) in response to oncogenes and DNA replication stress.

Vanzo R, Bartkova J, Merchut-Maya JM, Hall A, Bouchal J, Dyrskjøt L, Frankel LB, Gorgoulis V, Maya-Mendoza A, Jäättelä M, Bartek J.

Cell Death Differ. 2019 Aug 14. doi: 10.1038/s41418-019-0403-9. [Epub ahead of print]

PMID:
31409894
2.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Llobet SG, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2019 Jun 10;35(6):950-952. doi: 10.1016/j.ccell.2019.05.012. No abstract available.

3.

Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.

Majera D, Skrott Z, Bouchal J, Bartkova J, Simkova D, Gachechiladze M, Steigerova J, Kurfurstova D, Gursky J, Korinkova G, Cwiertka K, Hodny Z, Mistrik M, Bartek J.

Prostate. 2019 Mar;79(4):352-362. doi: 10.1002/pros.23741. Epub 2018 Nov 29.

PMID:
30499118
4.

DNA damage-induced dynamic changes in abundance and cytosol-nuclear translocation of proteins involved in translational processes, metabolism, and autophagy.

Bennetzen MV, Kosar M, Bunkenborg J, Payne MR, Bartkova J, Lindström MS, Lukas J, Andersen JS, Bartek J, Larsen DH.

Cell Cycle. 2018;17(17):2146-2163. doi: 10.1080/15384101.2018.1515552. Epub 2018 Sep 22.

5.

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S.

Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Erratum in: Cancer Cell. 2019 Jun 10;35(6):950-952.

6.

Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4.

Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J.

Nature. 2017 Dec 14;552(7684):194-199. doi: 10.1038/nature25016. Epub 2017 Dec 6.

7.

Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas.

Bartek J Jr, Fornara O, Merchut-Maya JM, Maya-Mendoza A, Rahbar A, Stragliotto G, Broholm H, Svensson M, Sehested A, Söderberg Naucler C, Bartek J, Bartkova J.

Mol Oncol. 2017 Aug;11(8):945-964. doi: 10.1002/1878-0261.12061. Epub 2017 Jun 17.

8.

Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress.

Chroma K, Mistrik M, Moudry P, Gursky J, Liptay M, Strauss R, Skrott Z, Vrtel R, Bartkova J, Kramara J, Bartek J.

Oncogene. 2017 Apr 27;36(17):2405-2422. doi: 10.1038/onc.2016.392. Epub 2016 Nov 14.

PMID:
27841863
9.

DNA replication stress mediates APOBEC3 family mutagenesis in breast cancer.

Kanu N, Cerone MA, Goh G, Zalmas LP, Bartkova J, Dietzen M, McGranahan N, Rogers R, Law EK, Gromova I, Kschischo M, Walton MI, Rossanese OW, Bartek J, Harris RS, Venkatesan S, Swanton C.

Genome Biol. 2016 Sep 15;17(1):185. doi: 10.1186/s13059-016-1042-9.

10.

FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome.

Kiiski JI, Fagerholm R, Tervasmäki A, Pelttari LM, Khan S, Jamshidi M, Mantere T, Pylkäs K, Bartek J, Bartkova J, Mannermaa A, Tengström M, Kosma VM, Winqvist R, Kallioniemi A, Aittomäki K, Blomqvist C, Nevanlinna H.

Int J Cancer. 2016 Dec 15;139(12):2760-2770. doi: 10.1002/ijc.30394. Epub 2016 Sep 19.

11.

DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.

Kurfurstova D, Bartkova J, Vrtel R, Mickova A, Burdova A, Majera D, Mistrik M, Kral M, Santer FR, Bouchal J, Bartek J.

Mol Oncol. 2016 Jun;10(6):879-94. doi: 10.1016/j.molonc.2016.02.005. Epub 2016 Mar 3.

12.

TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.

Moudry P, Watanabe K, Wolanin KM, Bartkova J, Wassing IE, Watanabe S, Strauss R, Troelsgaard Pedersen R, Oestergaard VH, Lisby M, Andújar-Sánchez M, Maya-Mendoza A, Esashi F, Lukas J, Bartek J.

J Cell Biol. 2016 Feb 1;212(3):281-8. doi: 10.1083/jcb.201507042. Epub 2016 Jan 25.

13.

A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.

Dietlein F, Kalb B, Jokic M, Noll EM, Strong A, Tharun L, Ozretić L, Künstlinger H, Kambartel K, Randerath WJ, Jüngst C, Schmitt A, Torgovnick A, Richters A, Rauh D, Siedek F, Persigehl T, Mauch C, Bartkova J, Bradley A, Sprick MR, Trumpp A, Rad R, Saur D, Bartek J, Wolf J, Büttner R, Thomas RK, Reinhardt HC.

Cell. 2015 Jul 2;162(1):146-59. doi: 10.1016/j.cell.2015.05.053. Erratum in: Cell. 2015 Aug 27;162(5):1169.

14.

REV7 counteracts DNA double-strand break resection and affects PARP inhibition.

Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S.

Nature. 2015 May 28;521(7553):541-544. doi: 10.1038/nature14328. Epub 2015 Mar 23.

15.

SETD2 loss-of-function promotes renal cancer branched evolution through replication stress and impaired DNA repair.

Kanu N, Grönroos E, Martinez P, Burrell RA, Yi Goh X, Bartkova J, Maya-Mendoza A, Mistrík M, Rowan AJ, Patel H, Rabinowitz A, East P, Wilson G, Santos CR, McGranahan N, Gulati S, Gerlinger M, Birkbak NJ, Joshi T, Alexandrov LB, Stratton MR, Powles T, Matthews N, Bates PA, Stewart A, Szallasi Z, Larkin J, Bartek J, Swanton C.

Oncogene. 2015 Nov 12;34(46):5699-708. doi: 10.1038/onc.2015.24. Epub 2015 Mar 2.

16.

Myc and Ras oncogenes engage different energy metabolism programs and evoke distinct patterns of oxidative and DNA replication stress.

Maya-Mendoza A, Ostrakova J, Kosar M, Hall A, Duskova P, Mistrik M, Merchut-Maya JM, Hodny Z, Bartkova J, Christensen C, Bartek J.

Mol Oncol. 2015 Mar;9(3):601-16. doi: 10.1016/j.molonc.2014.11.001. Epub 2014 Nov 15.

17.

A short acidic motif in ARF guards against mitochondrial dysfunction and melanoma susceptibility.

Christensen C, Bartkova J, Mistrík M, Hall A, Lange MK, Ralfkiær U, Bartek J, Guldberg P.

Nat Commun. 2014 Nov 5;5:5348. doi: 10.1038/ncomms6348.

PMID:
25370744
18.

Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: implications for the anti-tumor barrier concept and treatment.

Bartkova J, Hoei-Hansen CE, Krizova K, Hamerlik P, Skakkebæk NE, Rajpert-De Meyts E, Bartek J.

Mol Oncol. 2014 Dec;8(8):1667-78. doi: 10.1016/j.molonc.2014.07.001. Epub 2014 Jul 9.

19.

Immortalised breast epithelia survive prolonged DNA replication stress and return to cycle from a senescent-like state.

Maya-Mendoza A, Merchut-Maya JM, Bartkova J, Bartek J, Streuli CH, Jackson DA.

Cell Death Dis. 2014 Jul 24;5:e1351. doi: 10.1038/cddis.2014.315.

20.

JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks.

Watanabe S, Watanabe K, Akimov V, Bartkova J, Blagoev B, Lukas J, Bartek J.

Nat Struct Mol Biol. 2013 Dec;20(12):1425-33. doi: 10.1038/nsmb.2702. Epub 2013 Nov 17.

PMID:
24240613
21.

Androgen receptor signaling fuels DNA repair and radioresistance in prostate cancer.

Bartek J, Mistrik M, Bartkova J.

Cancer Discov. 2013 Nov;3(11):1222-4. doi: 10.1158/2159-8290.CD-13-0679.

22.

Overabundant FANCD2, alone and combined with NQO1, is a sensitive marker of adverse prognosis in breast cancer.

Fagerholm R, Sprott K, Heikkinen T, Bartkova J, Heikkilä P, Aittomäki K, Bartek J, Weaver D, Blomqvist C, Nevanlinna H.

Ann Oncol. 2013 Nov;24(11):2780-5. doi: 10.1093/annonc/mdt290. Epub 2013 Jul 29.

PMID:
23897704
23.

The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis.

Evangelou K, Bartkova J, Kotsinas A, Pateras IS, Liontos M, Velimezi G, Kosar M, Liloglou T, Trougakos IP, Dyrskjot L, Andersen CL, Papaioannou M, Drosos Y, Papafotiou G, Hodny Z, Sosa-Pineda B, Wu XR, Klinakis A, Ørntoft T, Lukas J, Bartek J, Gorgoulis VG.

Cell Death Differ. 2013 Nov;20(11):1485-97. doi: 10.1038/cdd.2013.76. Epub 2013 Jul 12.

24.

Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer.

Velimezi G, Liontos M, Vougas K, Roumeliotis T, Bartkova J, Sideridou M, Dereli-Oz A, Kocylowski M, Pateras IS, Evangelou K, Kotsinas A, Orsolic I, Bursac S, Cokaric-Brdovcak M, Zoumpourlis V, Kletsas D, Papafotiou G, Klinakis A, Volarevic S, Gu W, Bartek J, Halazonetis TD, Gorgoulis VG.

Nat Cell Biol. 2013 Aug;15(8):967-77. doi: 10.1038/ncb2795. Epub 2013 Jul 14. Erratum in: Nat Cell Biol. 2013 Oct;15(10):1260.

PMID:
23851489
25.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.

Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

26.

Macrophages, nitric oxide and microRNAs are associated with DNA damage response pathway and senescence in inflammatory bowel disease.

Sohn JJ, Schetter AJ, Yfantis HG, Ridnour LA, Horikawa I, Khan MA, Robles AI, Hussain SP, Goto A, Bowman ED, Hofseth LJ, Bartkova J, Bartek J, Wogan GN, Wink DA, Harris CC.

PLoS One. 2012;7(9):e44156. doi: 10.1371/journal.pone.0044156. Epub 2012 Sep 6.

27.

A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response.

Schepeler T, Lamy P, Hvidberg V, Laurberg JR, Fristrup N, Reinert T, Bartkova J, Tropia L, Bartek J, Halazonetis TD, Pan CC, Borre M, Dyrskjøt L, Orntoft TF.

Oncogene. 2013 Aug 1;32(31):3577-86. doi: 10.1038/onc.2012.381. Epub 2012 Aug 27.

PMID:
22926521
28.

TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes.

Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant C, Grøfte M, Bartkova J, Poulsen M, Oka Y, Bekker-Jensen S, Mailand N, Neumann B, Heriche JK, Shearer R, Saunders D, Bartek J, Lukas J, Lukas C.

Cell. 2012 Aug 17;150(4):697-709. doi: 10.1016/j.cell.2012.06.039. Epub 2012 Aug 9. Erratum in: Cell. 2014 Dec 4;159(6):1476-7.

29.

DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo.

Takacova S, Slany R, Bartkova J, Stranecky V, Dolezel P, Luzna P, Bartek J, Divoky V.

Cancer Cell. 2012 Apr 17;21(4):517-31. doi: 10.1016/j.ccr.2012.01.021.

30.

Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.

Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, Lee M, Moudry P, Bartek J Jr, Fischer W, Lukas J, Rich JN, Bartek J.

J Exp Med. 2012 Mar 12;209(3):507-20. doi: 10.1084/jem.20111424. Epub 2012 Mar 5.

31.

Thresholds of replication stress signaling in cancer development and treatment.

Bartek J, Mistrik M, Bartkova J.

Nat Struct Mol Biol. 2012 Jan 5;19(1):5-7. doi: 10.1038/nsmb.2220. No abstract available.

PMID:
22218289
32.

Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.

Pierceall WE, Sprott KM, Heikkinen T, Heikkila P, Alaparthi L, Aittomaki K, Al-Adhami M, Villegas-Bergazzi V, Meyer JL, Kutok JL, Bartkova J, Bartek J, Nevanlinna H, Weaver DT, Blomqvist C.

Hum Pathol. 2012 Sep;43(9):1363-75. doi: 10.1016/j.humpath.2011.08.018. Epub 2011 Dec 26.

PMID:
22204715
33.

MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer.

Peurala H, Greco D, Heikkinen T, Kaur S, Bartkova J, Jamshidi M, Aittomäki K, Heikkilä P, Bartek J, Blomqvist C, Bützow R, Nevanlinna H.

PLoS One. 2011;6(11):e26122. doi: 10.1371/journal.pone.0026122. Epub 2011 Nov 10.

34.

NQO1 expression correlates inversely with NFκB activation in human breast cancer.

Jamshidi M, Bartkova J, Greco D, Tommiska J, Fagerholm R, Aittomäki K, Mattson J, Villman K, Vrtel R, Lukas J, Heikkilä P, Blomqvist C, Bartek J, Nevanlinna H.

Breast Cancer Res Treat. 2012 Apr;132(3):955-68. doi: 10.1007/s10549-011-1629-5. Epub 2011 Jun 25.

PMID:
21706157
35.

Two new CHEK2 germ-line variants detected in breast cancer/sarcoma families negative for BRCA1, BRCA2, and TP53 gene mutations.

Manoukian S, Peissel B, Frigerio S, Lecis D, Bartkova J, Roversi G, Radice P, Bartek J, Delia D.

Breast Cancer Res Treat. 2011 Nov;130(1):207-15. doi: 10.1007/s10549-011-1548-5. Epub 2011 May 12.

PMID:
21562711
36.

Senescence-associated heterochromatin foci are dispensable for cellular senescence, occur in a cell type- and insult-dependent manner and follow expression of p16(ink4a).

Kosar M, Bartkova J, Hubackova S, Hodny Z, Lukas J, Bartek J.

Cell Cycle. 2011 Feb 1;10(3):457-68. Epub 2011 Feb 1.

PMID:
21248468
37.

Long-distance inflammatory and genotoxic impact of cancer in vivo.

Bartek J, Mistrik M, Bartkova J.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17861-2. doi: 10.1073/pnas.1013093107. Epub 2010 Oct 6. No abstract available.

38.

Heterochromatin marks HP1γ, HP1α and H3K9me3, and DNA damage response activation in human testis development and germ cell tumours.

Bartkova J, Moudry P, Hodny Z, Lukas J, Rajpert-De Meyts E, Bartek J.

Int J Androl. 2011 Aug;34(4 Pt 2):e103-13. doi: 10.1111/j.1365-2605.2010.01096.x. Epub 2010 Aug 1.

PMID:
20695923
39.

Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas.

Bartkova J, Hamerlik P, Stockhausen MT, Ehrmann J, Hlobilkova A, Laursen H, Kalita O, Kolar Z, Poulsen HS, Broholm H, Lukas J, Bartek J.

Oncogene. 2010 Sep 9;29(36):5095-102. doi: 10.1038/onc.2010.249. Epub 2010 Jun 28.

PMID:
20581868
40.

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J.

Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9.

41.

The combined status of ATM and p53 link tumor development with therapeutic response.

Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT.

Genes Dev. 2009 Aug 15;23(16):1895-909. doi: 10.1101/gad.1815309. Epub 2009 Jul 16.

42.

Aberrations of the MRE11-RAD50-NBS1 DNA damage sensor complex in human breast cancer: MRE11 as a candidate familial cancer-predisposing gene.

Bartkova J, Tommiska J, Oplustilova L, Aaltonen K, Tamminen A, Heikkinen T, Mistrik M, Aittomäki K, Blomqvist C, Heikkilä P, Lukas J, Nevanlinna H, Bartek J.

Mol Oncol. 2008 Dec;2(4):296-316. doi: 10.1016/j.molonc.2008.09.007. Epub 2008 Oct 7.

43.

NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer.

Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, Syrjäkoski K, Kallioniemi A, Kilpivaara O, Mannermaa A, Kosma VM, Uusitupa M, Eskelinen M, Kataja V, Aittomäki K, von Smitten K, Heikkilä P, Lukas J, Holli K, Bartkova J, Blomqvist C, Bartek J, Nevanlinna H.

Nat Genet. 2008 Jul;40(7):844-53. doi: 10.1038/ng.155. Epub 2008 May 30.

PMID:
18511948
44.

DNA damage signalling guards against activated oncogenes and tumour progression.

Bartek J, Bartkova J, Lukas J.

Oncogene. 2007 Dec 10;26(56):7773-9. Review.

PMID:
18066090
45.

Deregulated overexpression of hCdt1 and hCdc6 promotes malignant behavior.

Liontos M, Koutsami M, Sideridou M, Evangelou K, Kletsas D, Levy B, Kotsinas A, Nahum O, Zoumpourlis V, Kouloukoussa M, Lygerou Z, Taraviras S, Kittas C, Bartkova J, Papavassiliou AG, Bartek J, Halazonetis TD, Gorgoulis VG.

Cancer Res. 2007 Nov 15;67(22):10899-909.

46.

The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.

Tommiska J, Bartkova J, Heinonen M, Hautala L, Kilpivaara O, Eerola H, Aittomäki K, Hofstetter B, Lukas J, von Smitten K, Blomqvist C, Ristimäki A, Heikkilä P, Bartek J, Nevanlinna H.

Oncogene. 2008 Apr 10;27(17):2501-6. Epub 2007 Nov 5.

PMID:
17982490
47.

DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'.

Bartek J, Lukas J, Bartkova J.

Cell Cycle. 2007 Oct 1;6(19):2344-7. Epub 2007 Jul 18. Review.

PMID:
17700066
48.

DNA damage response in human testes and testicular germ cell tumours: biology and implications for therapy.

Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J.

Int J Androl. 2007 Aug;30(4):282-91; discussion 291. Epub 2007 Jun 15.

PMID:
17573848
49.

DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours.

Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J.

Oncogene. 2007 Nov 22;26(53):7414-22. Epub 2007 Jun 4.

PMID:
17546051
50.

Differences in DNA double strand breaks repair in male germ cell types: lessons learned from a differential expression of Mdc1 and 53BP1.

Ahmed EA, van der Vaart A, Barten A, Kal HB, Chen J, Lou Z, Minter-Dykhouse K, Bartkova J, Bartek J, de Boer P, de Rooij DG.

DNA Repair (Amst). 2007 Sep 1;6(9):1243-54. Epub 2007 Mar 21.

PMID:
17376750

Supplemental Content

Loading ...
Support Center